Benjamin Halladay, Chief Financial Officer at Esperion Therapeutics, Inc. (ESPR), sold 12,848 shares at $2.71 ($35K) on 2026-03-17, disclosed to the SEC on 2026-03-18.
Seasonal sale ($35k) by Chief Financial Officer — this insider has traded ESPR in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.71 | 6,424 | $17K | 50.0% |
| 2 | $2.71 | 6,424 | $17K | 50.0% |
| Total | $2.71 avg | 12,848 | $35K | 100% |
| Filing → |
| ESPR | SELL | 2025-09-18 | $20K | — | Filing → |
| ESPR | SELL | 2025-07-18 | $12 | — | Filing → |
| ESPR | SELL | 2025-06-18 | $8K | — | Filing → |